The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Outcome of 157 adult rhabdomyosarcoma (RMS) patients: A retrospective study from the French Group Sarcoma (GSF-GETO).
E. Bompas
No relevant relationships to disclose
L. Campion
No relevant relationships to disclose
A. Italiano
No relevant relationships to disclose
A. l. Cesne
Consultant or Advisory Role - Novartis; Pfizer; PharmaMar
Honoraria - Novartis; Pfizer; PharmaMar
M. Giaj Levra
No relevant relationships to disclose
C. Chevreau
No relevant relationships to disclose
S. Piperno-Neumann
No relevant relationships to disclose
N. Isambert
No relevant relationships to disclose
A. Thyss
No relevant relationships to disclose
M. Rios
No relevant relationships to disclose
J. Kurtz
No relevant relationships to disclose
C. Delcambre
No relevant relationships to disclose
J. Bay
No relevant relationships to disclose
F. Duffaud
Consultant or Advisory Role - Novartis; PharmaMar
Honoraria - Novartis; Pfizer
M. Trassard
No relevant relationships to disclose
P. Soulie
No relevant relationships to disclose
J. Blay
Consultant or Advisory Role - GlaxoSmithKline; Novartis; Pfizer; PharmaMar; Roche
Honoraria - GlaxoSmithKline; Novartis; Pfizer; PharmaMar; Roche
Research Funding - GlaxoSmithKline; Novartis; Pfizer; PharmaMar (I); Roche